Roche Gears Up For Potential Neuroscience Breakthroughs
Huntington’s Drug Could Get Nod in 2020
Neuroscience could be this decade’s big growth story, but clinical and market access challenges differ to oncology.
You may also be interested in...
Mayzent is the first oral treatment specifically indicated for patients with secondary-progressive multiple sclerosis and while it is expected to be a blockbuster, the company tells Scrip that educational programs for physicians are a priority.
The King's College London spin-out has gained £11.5m backing to take its ‘parallel CAR-T’ into the clinic.
An attempt to show efficacy even in younger people with mild COVID-19 symptoms has fallen flat in Phase II, and AT-527 will now lag behind rivals Merck and Pfizer.